

# Inherited and acquired variations in the hyaluronan synthase 1 (*HAS1*) gene may contribute to disease progression in multiple myeloma and Waldenstrom macroglobulinemia

Sophia Adamia,<sup>1</sup> Amanda A. Reichert,<sup>1</sup> Hemalatha Kuppasamy,<sup>1</sup> Jitra Kriangkum,<sup>1</sup> Anirban Ghosh,<sup>1</sup> Jennifer J. Hodges,<sup>1</sup> Patrick M. Pilarski,<sup>2</sup> Steven P. Treon,<sup>3</sup> Michael J. Mant,<sup>4</sup> Tony Reiman,<sup>1</sup> Andrew R. Belch,<sup>1</sup> and Linda M. Pilarski<sup>1</sup>

Departments of <sup>1</sup>Oncology and <sup>2</sup>Electrical and Computer Engineering, University of Alberta, Cross Cancer Institute, Edmonton, AB; <sup>3</sup>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; and <sup>4</sup>Department of Medicine, University of Alberta, Cross Cancer Institute, Edmonton, AB

**To characterize genetic contributions toward aberrant splicing of the hyaluronan synthase 1 (*HAS1*) gene in multiple myeloma (MM) and Waldenstrom macroglobulinemia (WM), we sequenced 3616 bp in *HAS1* exons and introns involved in aberrant splicing, from 17 patients. We identified a total of 197 *HAS1* genetic variations (GVs), a range of 3 to**

**24 GV/patient, including 87 somatic GV acquired in splicing regions of *HAS1*. Nearly all newly identified inherited and somatic GV in MM and/or WM were absent from B chronic lymphocytic leukemia, nonmalignant disease, and healthy donors. Somatic *HAS1* GV recurred in all hematopoietic cells tested, including normal CD34<sup>+</sup> hematopoietic progenitor cells**

**and T cells, or as tumor-specific GV restricted to malignant B and plasma cells. An in vitro splicing assay confirmed that *HAS1* GV direct aberrant *HAS1* intronic splicing. Recurrent somatic GV may be enriched by strong mutational selection leading to MM and/or WM. (Blood. 2008; 112:5111-5121)**

## Introduction

Splicing of pre-mRNA contributes to protein diversity in humans. Pre-mRNA splicing is regulated by *cis*- and *trans*-splicing elements, involving a complex repertoire of splicing factors, with spliceosome assembly directed by splicing motifs in the DNA template.<sup>1</sup> Evidence is accumulating for an association of defective gene splicing with susceptibility to and progression of cancer.<sup>2,3</sup> Genetic variations underlying cancer are linked to altered splicing.<sup>4,6</sup> Genetic changes in malignant cells can alter the genomic context of splice sites by activating otherwise weak or cryptic splice sites, leading to aberrant exon skipping, intron retention, or both.<sup>1</sup> Inherited polymorphisms and somatic (acquired) mutations underlie aberrant splicing in cancer.<sup>4,8</sup> Most aberrantly spliced products involve loss of tumor suppressor activity.<sup>3,6,7</sup> However, 2 genes, cyclin D1<sup>4,9</sup> and hyaluronan synthase 1 (*HAS1*),<sup>10-12</sup> undergo aberrant splicing to generate proteins with new functions or localizations that may directly promote cancer.

Hyaluronan synthases have been implicated in malignant transformation.<sup>13-16</sup> *HAS1* overexpression was described in patients with multiple myeloma (MM),<sup>10</sup> Waldenstrom macroglobulinemia (WM),<sup>11</sup> and colon,<sup>17</sup> ovarian,<sup>18,19</sup> bladder,<sup>20,21</sup> and endometrial carcinomas.<sup>22</sup> We identified a family of aberrant *HAS1* splice variants, termed *HAS1Va*, *HAS1Vb*, and *HAS1Vc*<sup>10</sup> in MM and WM that are undetectable in B-chronic lymphocytic leukemia (B-CLL) and healthy donors (HDs).<sup>10,11</sup> Aberrant intronic splicing of *HAS1* pre-mRNA, spanning exons 3 to 5, correlates with significantly reduced survival in MM.<sup>10</sup> In WM, up-regulation of *HAS1* intronic splice variants occurs in a majority of CD20<sup>+</sup> B-lineage cells, detected by single-cell reverse transcriptase-

polymerase chain reaction (RT-PCR).<sup>11</sup> *HAS1Va* has been detected in bladder cancer.<sup>20</sup>

Aberrant splicing results from genetic variations (GVs), including substitutions, deletions, and insertions, detected in the sequence of classical splicing elements and within exons and introns.<sup>23-30</sup> These mutations include missense mutations, which change amino acids and consequently protein function, and nonsense or silent mutations leading to frame-shifting and novel protein production.<sup>27,31-33</sup> "Deep" intronic mutations may cause aberrant splicing of disease-related genes by creating or strengthening cryptic splicing elements.<sup>34,35</sup> GV promote aberrant splicing in genes encoding *MLH1*, *MLH2*,<sup>8</sup> *CHEK2*,<sup>6</sup> *RB1*,<sup>36,37</sup> *p53*,<sup>5</sup> *NF1*,<sup>28</sup> *BRCA1*,<sup>38,39</sup> *PTEN*,<sup>40</sup> and the cystic fibrosis transmembrane conductance regulator.<sup>41</sup>

Here, the contributions of germ line origin or malignant-cell specific GV to aberrant *HAS1* splicing were determined by extensive sequencing of *HAS1* gene segments from buccal epithelial cells (BECs), hematopoietic progenitor cells (HPCs), T cells, B cells, and plasma cells (PCs) obtained from patients with MM and WM. BECs represent the germ line "host" genotype, whereas HPCs, T cells, B cells, and PCs represent normal and malignant components of the hematopoietic lineage in patients with MM and WM. We found a total of 197 GV in 17 patients with MM and WM. Nearly all of these GV were absent from 23 control subjects, including 4 with B-CLL, 11 with monoclonal gammopathy of undetermined significance (MGUS), and 8 HDs. In addition to 12 known *HAS1* polymorphisms, in 17 patients we found 46 novel germ line GV, 87 somatic GV, and 52 unclassified GV among

Submitted February 27, 2008; accepted August 29, 2008. Prepublished online as *Blood* First Edition paper, September 24, 2008; DOI 10.1182/blood-2008-02-141770.

The online version of this article contains a data supplement.

Presented in abstract form at the 49th annual meeting of the American Society

of Hematology, Atlanta, GA, December 2007.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.

© 2008 by The American Society of Hematology

all tested cell types. Among somatic GVs, defined as those that were absent from autologous BECs, 26 were found in presumptively normal HPCs and T cells from patients with MM and WM, and 61 tumor-specific GVs were found only in B cells and PCs of patients with MM or WM or both. An *in vitro* splicing assay confirmed that a combination of germ line and somatic GVs leads to aberrant *HAS1* splicing.

## Methods

### Patients and controls


The present study includes samples from 10 patients with MM (age range, 41-85 years; mean, 64 years), 7 patients with WM (age range, 44-76 years; mean, 63 years), and, as control subjects, 4 with B-CLL, 11 with MGUS (age range, 61-84 years), and 8 HDs (age range, 50-69 years, with the exception of 1 HD who was 30 years of age). Patients with MM included 5 with IgG myeloma and 5 with IgA myeloma; 8 had detectable bone lesions. There are no known familial forms of disease, and no familial relationships among the patients analyzed with MM and WM. The patients with MM and WM expressed at least one *HAS1* splice variant. Approximately 60% of patients have such variants.<sup>10,11</sup> Patients were recruited independently at the Cross Cancer Institute and the University of Alberta Hospital (Edmonton, AB), and the Dana-Farber Cancer Institute (Boston, MA). All patients were diagnosed according to the recommendations of the International Myeloma Working Group,<sup>42</sup> and the consensus guidelines from the 2nd International Workshop on Waldenstrom Macroglobulinemia.<sup>43</sup> Peripheral blood (PB), bone marrow (BM), and BEC samples were taken at the time of diagnosis or at follow-up, after approval from the University of Alberta and the Alberta Cancer Board Institutional Review Boards or the Dana-Farber Institutional Review Board; informed consent in accordance with the Declaration of Helsinki was obtained from all subjects. All patients and HDs included in this study were of white origin.

### Tissue and sample preparation

Tissue and sample preparation and cell sorting were conducted as previously described.<sup>44</sup> gDNA samples from sorted cells and unfractionated peripheral blood mononuclear cells (PBMCs) or BM cells (BMCs) were isolated using QIAamp DNA Blood mini kit (QIAGEN, Mississauga, ON) according to the manufacturer's instructions. For 17 patients with MM and WM sequencing of all indicated *HAS1* gene segments and *HAS1* minigenes was performed on populations of 6 sorted PB B cells, 3 sorted BM B cells, 2 sorted PCs, 6 sorted T cells, 8 sorted CD34<sup>+</sup> HPCs, 2 unfractionated PBMCs, 3 unfractionated BMCs, and 8 BECs. Among the 23 control subjects, *HAS1* gene segments were analyzed from purified B cells of 4 B-CLL (intron 4), unfractionated PBMCs from 11 MGUS, sorted B and T cells from 2 healthy donors and unfractionated PBMCs from 6 HDs.

### Cloning and sequencing

Cloning and sequencing of *HAS1* gene segments used gDNA isolated from BECs, purified cell subsets, BMCs, or PBMCs obtained from patients with MM, patients with WM, or HDs and PBMCs from MGUS and purified B cells from B-CLL. Patients with MM and WM expressed *HAS1* and its splice variants. The *HAS1* genomic segments from exon 3 to exon 5 were amplified, cloned, and sequenced using a series of primer sets (Figure 1; Table 1) spanning the region involved in the observed *HAS1* aberrant splicing (exons 3-4 and introns 3-4). The reverse and forward primers used in these PCR reactions were significantly overlapped to evaluate the accuracy of PCR and sequencing in multiple sequencing reactions (Figure 1). PCR products were cloned, and 3 to 19 subclones were sequenced in both directions for each *HAS1* gene segment from each subset of cells, using the ABI3130xl DNA capillary analysis system (Applied Biosystems, Foster City CA). For one small segment of intron 4 from one patient, only 2 subclones were sequenced. Because of primer overlap for *HAS1* gene segments, we obtained up to 60 sequencing reactions for each sample,



**Figure 1. Strategies for sequencing the *HAS1* gene segments.** Described are 2 strategies used to amplify the *HAS1* gene segments. Overlapping reverse and forward primers were designed to anneal with exons and introns of the *HAS1* gene to identify genetic variations that may contribute to aberrant *HAS1* splicing in patients with WM. Minigene sequencing in strategy 2 was used to determine whether the recurrent mutations were clustered. gDNA PCR and cloning were carried out as described in "Methods." We picked 24 to 48 subclones to screen and sequence inserts (gDNA PCR product of the *HAS1* gene segment) in the TOPO TA plasmid using the appropriate primer sets for each segment. While using the first strategy of amplifying *HAS1* gene segments from the patients or HDs, we cloned 7 or 3 segments from the exon 3 to exon 5 region of the *HAS1* gene using A or B primer sets, respectively. For each segment, 3 to 10 positive subclones were selected, and, for each cell subset, more than 50 plasmids were isolated and sequenced both directions using M13 and T7 sequencing primers. Using strategy 2, we cloned 30 *HAS1* minigene plasmids from MM and WM, and 33 minigenes from B-CLL and MGUS. B-CLL minigenes encompassed only intron 4. MGUS minigenes encompassed exon 3 to exon 5. Each plasmid was sequenced using overlapping *HAS1* gene-specific A and B primer sets. Because we used overlapping primers either in gDNA PCR (strategy 1) or for sequencing (strategy 2), we analyzed 50 to 60 sequencing reactions for exon-intron spanning segments of the *HAS1* gene. The *HAS1* gene segments of 2 HDs (B and T cells) were sequenced using strategy 1. The genetic variations identified in patients with MM and WM were assessed, based on a total of 4119 sequencing reactions.

which included the approximately 40 to 100 bp range of exon-intron boundaries of the *HAS1* gene.

For each subject, we also generated up to 15 minigenes of 3503 bp (chromosomal location 56912272-56908769) in length, which spanned gDNA of *HAS1* exon 3 to exon 5. A minigene is the product of a gDNA PCR reaction. Usually, this segment includes exons and introns of any given gene, preserving the linkages among genetic variations on the DNA strand that was copied. In our case, *HAS1* minigenes include the genomic sequence of *HAS1* exons 3, 4, and 5 and introns 3 and 4. The main purpose for using minigenes in this study was to determine whether recurrent GVs are expressed as clusters and if they belong to the same allele. Each minigene was sequenced in both directions using *HAS1* gene primer sets shown in Figure 1. Sequencing of *HAS1* minigenes allowed us to determine whether the recurrent GVs detected in patients occurred as a cluster of mutations. The regions of *HAS1* that were sequenced included exons 3 and 4, introns 3 and 4, and part of exon 5.

Overall, more than 4000 sequencing reactions were performed and analyzed. Sequencing runs included a defined patient sample to validate our sequencing analysis. In addition, cloning and sequencing were conducted by 7 different persons over the course of this study, and sequence analysis was performed by 3 different persons, all with consistent results. As a control, some samples were blinded and sequenced more than once, with consistent results. All PCR reactions were performed using High Fidelity Taq polymerase that has proofreading capability. For randomly chosen reactions, direct sequencing was done to verify the subcloning analysis.

Conditions for gDNA PCR were as follows: 50  $\mu$ L PCR reaction mix contained 50 ng gDNA, 5  $\mu$ L of 1XPCR buffer, 2 mM MgSO<sub>4</sub>, 0.2 mM dNTPs, 0.4 mM *HAS1* primer set (Figure 1), and 0.5 U High Fidelity Platinum Taq (Invitrogen, Carlsbad, CA). The PCR cycling parameters were as follows: denaturation for 5 minutes at 94°C, followed by denaturation for 30 seconds at 94°C, annealing for 40 seconds at 60°C, and extension at 68°C for 5 minutes for 35 cycles, with a final extension period of 10 minutes at 72°C. The *HAS1* PCR products were cloned into the pCR2.1 TOPO TA cloning system (Invitrogen) and sequenced using

**Table 1. Primer sets used for PCR and/or sequencing reactions**

HAS1 primers	Sequence 5' to 3'
5' exon 3	GGGGTCTGTGCTGATCCTGG
3' exon 3	GCTTCCAGTTTTATCCCATC
5' intron 3	CTTCCACTGTGTATCCTGCATC
3' intron 3	AACTGCTGCAAGAGTTATTCC
5' exon 4	TGGGGTTGGAAGTGGAGATG
3' exon 4	CATGCACACACGCTAGGATA
5' intron 4a	GCTCAGCATGGGTTATGCTA
3' intron 4a	GTATCCCCGACGTTAAACA
5' intron 4b	TTGGGATAATCCAGGGGAAT
3' intron 4b	CAAGATGGGTGTGGTTGCTA
5' intron 4c	GGTAGCAACCACCCATCT
3' intron 4c	AGGAATGAGGGCATCATCG
5' exon 5a	CTCGCCCCGTGCAGGTACA
3' exon 5a	AGGCCCAAGCAGCAGCAGCGCG
5' exon 3-exon 4*	ATGGGATAGCTTGGAGTCA*
3' exon 3-exon 4*	CCCATCCAAAACCCACTGCA*
5' exon 4-intron 4 (a)*	GGAGACCAAGGTAGCACAGT*
3' exon 4-intron 4 (a)*	GTCTCTTGCCCTTCTACTT*
5' exon 4-intron 4 (b)*	CAAGGGTGGTGGATAGGAAGTT*
3' exon 4-intron 4 (b)*	CCTCAGGCACTCCACTTAACAC*
5' intron 4-exon 5 (a)*	GGGCACGATCATGGCTCACT*
3' exon 4-intron 4 (a)*	GAGGTAGGGGATCACTTGA*
5' intron 4-exon 5 (b)*	CCCCAGGGAGCAGCGATGA*
3' exon 4-intron 4 (b)*	GCACGGGGCGAGGAATGAG*
5' minigene	CTTCCACCTTACAGGTCTGTGACT
3' minigene	CCACTCTGGTTCATGGTACTA
5' intron 4c (T)	GCAAATACTATCTACTGGTCTAAGC
3' intron 4c (T)	TGTGTAGAATAGGTGGATAATGGT
M13R	CAGGAACAGCTATGAC
T7	TAATACGACTCACTATAGGG

Primer set intron 4c (T) was used to verify common motif sequences 1st T, 2nd T, and TTTA stretches. Primer sequences were used in sequencing reactions only.

BigDye V1.1 and V1.1 chemistry (Applied Biosystems) according to the manufacturer's instructions.

### Sequencing analysis

Obtained sequences were analyzed with the use of sequencing analysis software, whereas alignment was done with the use of SeqScape software; both software packages were provided by Applied Biosystems. Obtained sequences were compared with the *HAS1* reference sequence reported in the National Center for Biotechnology Information (NCBI) database.<sup>45</sup> For the analysis reported here, GVs from patients with MM and WM were included if they were present on at least 20% of the subclones sequenced for that sample or were identified in more than one patient. *HAS1* GVs were identified as recurrent if they were detected in more than one patient. GVs were categorized as hematopoietic/germ line origin if no BECs were available for sequencing. GVs were categorized as confirmed germ line only if BEC sequences were available for comparison with hematopoietic cells. Other categories were as reported in "Results." *HAS1* sequences from 23 control subjects were screened for the presence, or not, of GVs previously identified in patients with MM or WM or both.

### In vitro splicing assay

A *HAS1* minigene, a segment of *HAS1* gDNA, extending from exon 3 to exon 5 (NC\_000049) was amplified from gDNA of a patient with WM who expressed *HAS1Vb* transcripts. *HAS1* minigene includes sequence of the *HAS1* exons 3, 4, and 5 and introns 3 and 4. The amplified *HAS1* minigene was joined to the upstream sequence of *HAS1* cDNA, including exon 1 and 2, at *SmaI* site located within exon 3 to generate a hybrid *HAS1* cassette composed of cDNA linked to a gDNA fragment (Figure 3F). Four subclones of the hybrid fragments were cloned into pcDNA3 (Invitrogen), yielding pcDNA3*HAS1*-g3-4-5 constructs. RNA splicing was analyzed by transfecting the construct into HeLa cells using Lipofectamine 2000 (Invitrogen)

following the manufacturer's instructions. Cells were harvested 24 hours after transfection for RT-PCR. We made a plasmid construct containing full-length *HAS1* cDNA, pcDNA3-*HAS1*-FL (A.G., H.K., and L.M.P., manuscript submitted), for use as a positive control in the transfection experiments.

Total RNA was isolated from transfected HeLa cells using a standard Trizol isolation method (Invitrogen). RT-PCR reactions were conducted following a standard protocol (Invitrogen). PCR primer sequences used in the RT-PCR reactions are as follows: *HAS1FL* sense primer, 5'-GCGGTCCTCTAGGCCTATATAGGA-3'; *HAS1FL* antisense primer, 5'-CTGGAGGTGTACTTGGTAGCATAA-3'; *HAS1Vb* sense primer, 5'-GCGGTCCTCTAGAATCCTGCCAG-3'; and *HAS1Vb* antisense primer, 5'-CTGGAGGTGTACTTGCACGGGGGC-3'.

### Bioinformatic analysis

To evaluate recurrent GVs leading to aberrant *HAS1* splicing in patients, we first identified classical splicing sites (5' and 3' SS, BP, PPT) and splicing elements (putative exonic and intronic enhancers and suppressors: ESE, ISE, ESS, and ISS) located within the alternatively spliced exons and introns of this gene using "ESE finder" web interface (release 2.0). In addition, *cis*-splicing elements (exonic and intronic enhancers [ESE, ISE] and suppressors [ISE, ISS], splicing branch point [BP] and polypyrimidine tract [PPT]) of wild-type and mutated *HAS1* gene segments were mapped and evaluated using the publicly available bioinformatic software, Splicing Signal Analysis tools (<http://www.ebi.ac.uk/asd-srv/wb.cgi>). Next, GVs detected through cloning and sequencing were mapped with the splicing elements identified by the above-mentioned methods. Each GV was evaluated alone and in combination to determine whether any of these variations or clusters of GVs had a predicted effect on the activation of cryptic splice sites in the *HAS1* gene. Activation of cryptic splice sites was determined using the Splice Site Prediction tool (<http://www.cbs.dtu.dk/biolinks/pserv2.php>).

## Results

### Sequencing analysis of *HAS1* gene segments in MM and WM

Because of their involvement in the aberrant splicing of *HAS1* pre-mRNA, we sequenced genomic segments (exons and introns) or minigenes or both of *HAS1* from exon 3 to exon 5 (3616 bp or 3503 bp, chromosomal location at 56912295-56908679 bp or 56912272-56908769 bp). We obtained samples from 10 patients with MM and 7 patients with WM expressing *HAS1* splice variant transcripts and sequenced genomic *HAS1* from defined cell subsets. To avoid false detection of GVs, 3 to 19 subclones or minigenes were sequenced in both directions for each cell subset. Only those GVs present in 20% or more of the subclones for a given sample are reported here.

GVs were defined as recurrent if they were detected in at least 2 patients. Sequencing analysis identified 50 recurrent and 147 unique *HAS1* GVs that include substitutions, insertions, and deletions (Tables 2-4; Table S1, available on the *Blood* website; see the Supplemental Materials link at the top of the online article). We identified 46 novel germline and 87 somatic *HAS1* GVs (acquired in hematopoietic or tumor cells but absent from BECs), as well as 52 unclassified novel GVs and 12 frequent NCBI single nucleotide polymorphisms (SNPs). A median of 23 GVs/patient were identified (range, 3-24 GVs). The 50 recurrent *HAS1* GVs included 28 inherited (16 germ line origin GVs and 12 NCBI-SNPs), 10 acquired hematopoietic origin, and 7 acquired tumor-specific GVs (Tables 2,3; classification of GVs is described in "Classification of GVs detected in patients with MM and WM"). We also detected 5 GVs that were classified as hematopoietic/germ line origin, because no BECs were available to confirm germ line or

**Table 2. Distribution of *HAS1* GVs on *HAS1* exons and introns**

Classification of GVs	HAS1 gene							
	Exon 3		Intron 3		Exon 4		Intron 4	
	U	R	U	R	U	R	U	R
<b>Patients with MM and WM (n = 17)</b>								
Tumor specific	8	2	6	1	0	0	40	4
Hematopoietic origin	1	2	0	1	0	2	15	5
Hematopoietic/germline origin	9	1	11	2	1	0	26	2
Germline origin	4	5	9	1	0	0	17	10
NCBI-SNP	0	1	0	3	0	0	0	8
Total	22	11	26	8	1	2	98	29
<b>Controls (n = 23)</b>								
Tumor specific	0	0	0	0	0	0	1	0
Hematopoietic origin	0	0	0	0	0	0	0	0
Hematopoietic/germline origin	2	0	0	0	0	0	5	0
Germline origin	0	0	0	0	0	0	0	4
NCBI-SNP	0	1	0	3	0	0	0	8
Total	2	1	0	3	0	0	6	12

Distribution of unique (U) and recurrent (R) of GVs on *HAS1* gene exon 3 to 4 and introns 3 to 4 from patients with MM and WM. We have detected a total of 196 unique and recurrent GVs in 17 patients with MM and WM. Among these GVs, 61 are tumor specific, 26 are hematopoietic origin, 52 are hematopoietic/germline origin, 46 are germline origin, and 11 are NCBI SNPs. Some of the GVs detected in hematopoietic cells were classified as hematopoietic/germline origin because no BECs were available for these patients to confirm germ line or hematopoietic origin. We also detected sporadic substitutions, each in only one subclone from one individual HD, that were not detected in patients with MM or WM and are not reported in the NCBI database.

hematopoietic origin for the patients in whom these GVs were detected. Each category of recurrent *HAS1* GVs was detected in 2 to 15 of the 17 patients with MM and WM analyzed (Table 4). Both inherited and acquired sets included GVs recurrent only in MM (7 of 50; ~14%), only in WM (10 of 50; ~20%), or shared by MM and WM (34 of 50; ~68%) (Table 3).

The presence or not of GVs from the 17 patients with MM and WM was determined for the NCBI *HAS1* gene sequence and the *HAS1* exons and introns from 23 control subjects (Table 2). *HAS1* segments were sequenced from 4 B-CLL, 11 MGUS, and 8 HDs. Most of the control subjects expressed the NCBI SNPs found in MM and WM, although 4 of the HDs expressed only major alleles. Four germ line GVs were detected in B-CLL and a subset of MGUS, which were found in only a minority of subclones or were absent from the HDs; these may be as yet unreported polymorphisms. Of 147 unique GVs, 8 were detected sporadically in HDs or MGUS, in only a minority of subclones per sample, and, with one exception, each GV was found in only 1 of the 23 control subjects. Seven of the 8 unique GVs found in control subjects were classified as germline/hematopoietic origin (Table 3). This indicates that the majority of the *HAS1* GVs reported here for patients with MM and WM, including all of the recurrent acquired GVs, appear restricted to MM and WM.

#### Classification of GVs detected in patients with MM and WM

GVs were classified as follows: (1) GVs detected only in B cells and PCs from patients were classified as "tumor-specific." These GVs were absent from T cells, HPCs, and BECs, as well as from control subjects; the stage of disease during which these were acquired is unknown. (2) GVs identified in hematopoietic cell populations but absent from BECs were defined as being of "hematopoietic-origin." They were found in all hematopoietic populations tested from MM and WM, including HPCs and T cells (nonmalignant) and B cells and PCs (malignant). Their absence from BECs indicates that these are somatic GVs acquired by presumptively normal HPCs and transmitted to their T- and B-lineage progeny. Hematopoietic-origin GVs were absent from cell subsets of control subjects. (3) Newly identified *HAS1* GVs identified in all cell populations, including BECs, were classified as

"germline-origin," 4 of which were detected in control subjects and may be unreported SNPs. In MM and WM, these substitutions were frequently homozygous, defined by their presence in every subclone sequenced for a given patient. We also identified a high frequency of the mutated alleles for 12 NCBI *HAS1* SNPs. The mutated alleles of these SNPs were present in most patients with MM and WM and were also detectable in control subjects (Table 2).

#### GVs detected in MM and WM

Tumor cells from MM and WM had 4 or more tumor-specific GVs in their B cells, PCs or both, but the majority of these tumor-specific GVs were unique (Figure 2B). In addition, 10 (59%) of 17 patients with MM and WM carried recurrent tumor-specific *HAS1* GVs in B cells and /PCs, whereas 11 (65%) had recurrent hematopoietic-origin GVs and 16 (94%) had recurrent germline-origin GVs (Table 4). The type, genomic location, and the distribution of recurrent GVs in MM and WM are reported in Table 3. None of the recurrent somatic GVs were found in control subjects.

Among the 7 recurrent tumor-specific (TS) *HAS1* GVs, 4 were detected only in WM and 3 were shared by WM and MM. Among these GVs 2 (no. 1TS and no. 2TS) are missense transversions and one, no. 5TS, is a deletion. Other recurrent GVs on intron 3 and intron 4 are transitions (Table 3). Furthermore, groups of tumor-specific GVs are coexpressed in the same patients. For example, exon 3 no. 1TS, intron 3 no. 3TS, and intron 4 no. 6TS are coexpressed together; a second coexpressed group included no. 2TS on exon 3 and no. 7TS on intron 4.

For 10 recurrent GVs of hematopoietic origin (HO), distributed across 65% of patients, 6 (50%) recur in both MM and WM, whereas 3 HO GVs (40%) are specific to MM and 1, no. 3HO (10%), is specific to WM (Table 3). Acquired hematopoietic-origin GVs were detected in as many as 5 different patients.

Of 16 recurrent germline origin (GO) *HAS1* GVs (defined by their presence in BECs), the majority are on exon 3 or intron 4. Most novel germline GVs (11 of 16) are shared by patients with MM and WM, with 3 (no. 9GO, no. 10GO, no. 15GO) recurring only in MM and 2 (no. 6GO, no. 8GO) recurring only in WM (Table 3). These may be candidate SNPs not yet reported. The sequencing analysis also detected mutated alleles of 12 NCBI-SNPs. These *HAS1* SNPs are found in 88%

**Table 3. Recurrent GVs and their distribution in patients with MM and WM**

	Chromosomal location	Nucleotide change	AA changes	Type of GVs	Recurrence of GVs in MM and WM*
<b>Tumor specific GVs</b>					
Exon 3	56912068	a>T	Tyr>Phe	1TS	2 WM
Exon 3	56912051	t>A	Cys>Ser	2TS	1 MM and 1 WM
Intron 3	56911759†	a>T		3TS	1 WM
Intron 3	56911759†	a>G		3TS	1 WM
Intron 4	56909899	a>G		4TS	2 WM
Intron 4	56909573	del.-c		5TS	1 MM and 1 WM
Intron 4	56909521	t>C		6TS	1 MM and 1 WM
Intron 4	56909482	t>C		7TS	2 WM
<b>Hematopoietic origin GVs</b>					
Exon 3	56912079	t>C	Ala>Ala	1HO	2 MM and 1 WM
Exon 3	56912077	g>A	Cys>Try	2HO	1 MM and 1 WM
Intron 3	56911668	a>G		3HO	2 WM
Exon 4	56911348	g>C	Arg>Pro	4HO	1 MM and 3 WM
Exon 4	56911346	a>T	Met>Leu	5HO	1 MM and 3 WM
Intron 4	56910198	a>C		6HO	2 MM
Intron 4	56910041	g>T		7HO	1 MM and 4 WM
Intron 4	56909423	t>C		8HO	2 MM
Intron 4	56909270	a>G		9HO	1 MM and 1 WM
Intron 4	56909186	a>G		10HO	2 MM
<b>Germline origin</b>					
Exon 3	56912080	c>T	Ala>Val	1GO	1 MM and 1 WM
Exon 3	56912058	t>C	Cys>Cys	2GO	1 MM and 1 WM
Exon 3	56912056	t>C	Val>Ala	3GO	3 MM and 1 WM
Exon 3	56912051	t>C	Cys>Arg	4GO	3 MM and 1 WM
Exon 3	56912041	g>A	Gly>Asp	5GO	1 MM and 1 WM
Intron 3	56911526	g>A		6GO	2 WM
Intron 4	56910856	t>C		7GO	1 MM and 1 WM
Intron 4	56910811	a>G		8GO	2 WM
Intron 4	56910410	a>G		9GO	2 MM
Intron 4	56910219	a>G		10GO	2 MM
Intron 4	56909762	ins(Ts)		11GO	6 MM and 7 WM
Intron 4	56909764	ins (Ts)		12GO	3 MM and 2 WM
Intron 4	56909589	del or ins (T)s		13GO	7 MM and 7 WM
Intron 4	56909447	del or ins (TTTA)s		14GO	6 MM and 5 WM
Intron 4	56909315	c>T		15GO	4 MM
Intron 4	56909217	c>T		16GO	4 MM and 1 WM
<b>Hematopoietic/germline origin</b>					
Exon 3	56912197	a>G	Asp>Gly	1H/G	1 MM and 1 WM
Intron 3	56911983	a>G		2H/G	2 MM
Intron 3	56911977	a>G		3H/G	1 MM and 1 WM
Intron 4	56910790	a>C		4H/G	2 WM
Intron 4	56909253	g>A		5H/G	2 WM
<b>NCBI-SNPs</b>					
Exon 3	56912163	c>T	Asp>Asp	rs 11084111	7 MM and 2 WM
Intron 3	56911889	g>A		rs 11084110	8 MM and 2 WM
Intron 3	56911831	g>A		rs 11084109	8 MM and 7 WM
Intron 3	56911750	t>A		rs 11669079	8 MM and 7 WM
Intron 4	56910770	g>C		rs 11667974	3 MM and 1 WM
Intron 4	56910738	t>G		rs 11667949	8 MM and 7 WM
Intron 4	56910711	g>A		rs 7254072	8 MM and 7 WM
Intron 4	56910493	g>C		rs 4802850	4 MM and 3 WM
Intron 4	56910155	c>A		rs 4802849	5 MM and 4 WM
Intron 4	56910154	c>G		rs 4802848	5 MM and 4 WM
Intron 4	56909763	c>T		rs 8104157	8 MM and 7 WM
Intron 4	56909604	ins T		rs 11438660	8 MM and 7 WM

Details are included of recurrent GVs that were detected in MM and WM, in exons and introns. TS indicates tumor specific GVs; HO, hematopoietic origin GVs; GO, germline origin GVs; H/G, hematopoietic/germline GVs; AA, amino acid; ins, insertion; del, deletion. GVs are numbered according to their position on exons and introns.

\*The numbers represent the number of patients with MM or WM or both in whom the GV was recurrent. A total of 49 chromosomal positions in *HAS1* harbored GVs.

†Two different mutated alleles were detected, yielding an aggregate of 50 recurrent GVs.

of the patients with MM and WM analyzed. Coding GVs detected on exon 3 and 4 (inserts in Figure 2B) were all shared by patients with MM and patients with WM.

Five recurrent GVs were provisionally classified as “hematopoietic/germline-origin” because no BECs were available for the

patients analyzed. Of these 5 GVs, 2 were shared by MM and WM, one was specific to MM, and 2 were specific to WM (Table 3).

As indicated above, 3 tumor-specific and 6 hematopoietic-origin *HAS1* GVs were shared by MM and WM. The existence of these shared, somatically acquired GVs suggests that there may

**Table 4. Number of persons in whom recurrent *HAS1* GVs were detected**

Type	Tumor	Hematopoietic	Germline	Germline/hematopoietic	NCBI-SNP
<b>MM and WM Patients (n = 17)</b>					
Percentage of patients with the indicated type of <i>HAS1</i> GVs (n/n)	59 (10/17)	65 (11/17)	94 (16/17)	41 (7/17)	88 (15/17)
No. of patients in whom <i>HAS1</i> GVs were recurrent	2-3	2-5	2-14	2-4	4-15
<b>Controls (n = 23)</b>					
Percentage of controls with recurrent <i>HAS1</i> GVs	0	0	4-39	0	39-83
No. of controls in whom <i>HAS1</i> GVs were recurrent	0	0	1-6	0	2-14

A patient or control was counted as having the indicated type of GV if at least one such GV was detected in the samples that were sequenced.


exist fundamental similarities in the events that underlie development and progression of MM and WM

**Linked clusters of GVs are detected in *HAS1* minigenes**

Our sequencing analysis showed that recurrent GVs are distributed as linked clusters, as distinct from random locations (Table 5). The linked clusters of GVs described in Table 5 are distributed in the vicinity of splicing elements. *HAS1* minigene sequencing identified 3 distinct clusters of GVs that include 3 NCBI-SNPs and germline/hematopoietic origin GVs that are detected within a specific sequence stretch of intron 4 (first “T” stretch, second “T”

stretch, and TTTA repeats; shown in Figure 2B), near splicing elements at the 3’ end of intron 4, where partial intron retention leads to *HAS1*Vb transcripts. These GVs and NCBI-SNPs are present in every cluster detected in patients with MM and WM, and will be referred to as a “common motif.” The common motif appears to cluster with other recurrent *HAS1* GVs (Figure 2B).

The GV clusters in WM were compared with those in MM, referred to as “WM clusters” or “MM clusters,” respectively, both including the common motif. Interestingly, GVs comprising MM GV cluster no. 3 and WM GV cluster no. 3 are identical with the exception of a germline origin mutation in MM exon 3



**Figure 2. Distribution of *HAS1* GVs.** (A) Cell type distribution of *HAS1* GVs detected in patients with MM and WM. Mutations identified in various types of cells from patients with MM were classified as tumor specific, hematopoietic and germline–origin based on their occurrence in these cells. HPCs indicates CD34<sup>+</sup>45<sup>low</sup> HPCs from mobilized blood of patients with MM or bone marrow aspirates from patients with WM; BECs indicate buccal epithelial cells. (B) Distribution of GVs in genomic *HAS1*. This figure shows relative distribution of GVs detected in patients with MM and WM. Recurrent NCBI-SNPs are absent from this figure. The inserts detail sets of GVs located at the boundary of exon 3 and exon 4, respectively. GVs are represented by yellow rings. On the figure, the first break on intron 4 represents 180 nucleotides, whereas the second break represents 100 nucleotides. 1st “T,” 2nd “T,” and “TTTA” are the common motif detected in patients with MM and WM. The spaces between mutations are arranged according to a scale of 50 bp = 4 mm.

**Table 5. Clusters of GV mutations detected in *HAS1* gene exons and introns from patients with MM and WM**

	Nucleotide changes	Chromosomal location	Type	Effects on the protein	Cluster*
<b>GVs clusters detected in MM patients</b>					
Exon 3	c>T	56912163	NCBI rs 1108411		1, 2, 3
Exon 3	t>C	56912056	Germline origin	Val>Ala	1
Intron 4	g>C	56910770	NCBI rs 11667974		1
Intron 4	c>T	56109315	Germline origin		2
Intron 4	c>T	56109217	Germline origin		2
Intron 4	inst T	56909764	Germline origin		2
Exon 3	t>C	56912051	Germline origin	Cys>Arg	3
Intron 4	g>C	56910493	NCBI rs 4802850		3
Intron 4	c>A	56910155	NCBI rs 4802849		3
Intron 4	c>G	56910154	NCBI rs 4802848		3
<b>GVs clusters detected in WM patients</b>					
Exon 3	a>T	56912068	Tumor specific	Tyr>Phe	1
Intron 3	a>G	56911668	Tumor specific		2
Exon 4	a>T	56911346	Hematopoietic origin	Met>Leu	2
Exon 4	g>C	56911348	Hematopoietic origin	Arg>Pro	2
Intron 4	g>t	56910041	Hematopoietic origin		2
Intron 4	t>C	56909252	Hematopoietic/germline origin		3
Intron 4	c>G	56910154	SNP-NCBI rs 4802848		3
Intron 4	c>A	56910155	SNP-NCBI rs 4802849		3
Intron 4	g>C	56910493	SNP-NCBI rs 4802850		3
<b>Common motifs</b>					
Intron 3	t>A	56911750	SNP-NCBI rs 11669079		
Intron 3	g>A	56911831	SNP-NCBI rs 11084109		
Intron 3	g>A	56911889	SNP-NCBI rs 11084110		
Intron 4	inst T	56909604	SNP-NCBI rs 11438660		
Intron 4	inst (TTTA)s	56909447	Germline origin		
Intron 4	del (TTTA)s	56909447	Germline origin		
Intron 4	inst/del (T)s	56909589	Germline origin		
Intron 4	inst (Ts)	56909762	Germline origin		
Intron 4	c>T	56909763	SNP-NCBI rs 8104157		
Intron 4	g>A	56910711	SNP-NCBI rs 7254072		
Intron 4	t>G	56910738	SNP-NCBI rs 11667949		

\*The first GV cluster of MM includes the common motif plus a recurrent hematopoietic origin missense mutation t>C (CH56912056) detected on exon 3 and NCBI-SNP rs 11667974. The second MM GV cluster comprises the common motif and 2 additional germline GV mutations, both on intron 4. The third MM GV cluster includes the common motif with an additional one germline origin missense t>C substitution (Cys>Arg) on exon 3 and 3 NCBI-SNPs on intron 4. All patients with MM were homozygous for mutated alleles of NCBI-SNPs included in the third GV cluster. WM GV cluster 1 includes the common motif plus a recurrent tumor-specific missense mutation a>T (Tyr>Phe, CH56912068) detected on exon 3. The second WM GV cluster includes the common motif and 4 additional hematopoietic origin GV mutations, missense mutations, a>T (CH56911346) and g>C (CH56911348) in exon 4, that lead to amino acid changes Met>Leu and Arg >Pro, respectively, one tumor specific in intron 4 (CH56910041), and one recurrent tumor-specific transition (CH56911668) in intron 3. The third WM GV cluster includes the common motif with an additional 4 GV mutations all detected in intron 4, 1 hematopoietic origin, and 3 NCBI-SNPs. Similar to patients with MM, all patients with WM were homozygous for mutated alleles of NCBI-SNPs included in any clusters.

(CH56912051) instead of the hematopoietic/germline GV in intron 4 (CH56909252) for WM cluster no. 3. Two other *HAS1* GV clusters from patients with MM or WM include the common motif plus other recurrent GV mutations (Table 5). MM and WM clusters appear to harbor abnormalities that may accompany early stages of malignancy or characterize progression events or both.


#### Recurrent mutations detected in intron 4 promote *HAS1* gene aberrant splicing

Bioinformatic analysis predicted that *HAS1* GV mutations lead to splicing events that generate *HAS1Vb*, the variant most significantly correlated with poor outcome (Figure 3A-E; S.A., manuscript in preparation).<sup>10</sup> We constructed a *HAS1* minigene splicing cassette derived from gDNA of a patient with WM whose cells expressed *HAS1Vb* transcripts. This *HAS1* cassette was used in an in vitro splicing assay to verify that *HAS1* GV mutations from WM could direct the splicing of *HAS1Vb*. The splicing construct incorporating the *HAS1* gDNA segment from exon 3 to exon 5 was transfected into HeLa cells, which do not otherwise express full-length *HAS1* or the aberrant *HAS1* splice variants (Figure 3F). Sequencing analysis identified 2 unique substitutions in

exon 3 and 2 in intron 4, as well as the common motif on *HAS1* minigene cassettes. After transfection of HeLa cells with the *HAS1* minigene cassettes, we detected aberrantly spliced *HAS1Vb* transcripts and normally spliced full-length *HAS1* (Figure 3F). Sequencing of the *HAS1Vb* PCR product confirmed its identity as *HAS1Vb*. This indicates that HeLa cells conserve the *trans*-splicing elements (small ribonuclear proteins) required for aberrant splicing of *HAS1* pre-mRNA, but the *HAS1Vb* transcript is spliced only when *cis*-elements of the WM *HAS1* template are introduced by the splicing construct.

## Discussion

Sequencing of the *HAS1* gene in patients with MM and WM evaluated genetic contributions to the aberrant intronic splicing of *HAS1* pre-mRNA that correlates with significantly reduced overall survival.<sup>10</sup> We report the existence of novel inherited (germline) and acquired (somatic) GV mutations in regions of the *HAS1* gene involved in aberrant splicing events. Somatic *HAS1* GV mutations appear to accumulate throughout hematopoietic development,



**Figure 3. Bioinformatic model.** Clusters of recurrent GVs facilitate aberrant splicing of *HAS1* gene in patients with MM to create the intronic *HAS1*Vb splice variants. In this analysis we used the web-based bioinformatic tool ESE finder V2. Results were evaluated using ESE V3 ([http://rulai.cshl.edu/cgi-bin/tools/ESE3/ese\\_finder.cgi](http://rulai.cshl.edu/cgi-bin/tools/ESE3/ese_finder.cgi)). For more detailed analysis we used ASD (The Alternative Splicing Database; workbench bioinformatics tools). Using these tools, we evaluated the distribution of splicing elements in *HAS1* exons 3 and 4 and introns 3 and 4 of wild-type and mutated sequences. (A) Relative distribution of recurrent mutations detected in patients with MM and WM is shown, and the accumulation of 2 important splicing cofactors, hnRNP I (PTB) and hnTNP A, is shown in exon 4 and introns 3 and 4. (B-D) The location on the *HAS1* gene where the aberrations occur. (E) Predicts the effect of recurrent GVs on *HAS1* splicing. (D), The red letters "A" and "Y" represent activated splicing branch point (BP) and polypyrimidine tract (PPT) of splicing, respectively, and gray letters "A" and "Y" represent native BP and PPT. Description of the model. No differences were found between wild-type and mutated exon 3 with respect to the accumulation of hnRNPs which bind mainly splicing suppressors and promote exon exclusion. However, in mutated exon 4, compared with wild-type exon 4 and in mutated exon 3, bioinformatic analysis predicted a massive accumulation of hnRNPs, including hnRNP I (PTB, polypyrimidine tract binding protein), which is distributed across the entire mutated exon 4 (A,B). As suggested in the diagram, the binding of PTBs at several sites of an exon could cause a loopout of this exon, and subsequently these types of exons become inaccessible for the assembly of the spliceosome (B,C,E). The analysis did not predict any significant differences between wild-type and mutated intron 3 with respect to Serine/Arginine-rich proteins (SRs) or the distribution of hnRNP binding motifs. In addition, no significant difference was found when BP and PPT were mapped on wild-type and mutated intron 3. However, for mutated intron 4, the existence of alternative splicing branch points were predicted. These alternative BPs are located upstream of the alternative PPT (D). In addition, splicing element analysis of wild-type and mutated intron 4 showed an accumulation of a significant number of SR and hnRNP binding motifs in mutated intron 4. Among them, the most significant predicted difference that contributes to intronic splicing of *HAS1* is recruitment of U2AF65 protein by the alternative PPTs (D). These predicted PPT sequences overlap with the 1st and 2nd "T" stretches and TTTA repeats of mutated intron 4 (the common motif) where the MM clusters of GVs are located. The protein U2SF65 is known to be responsible for the recruitment of SFs to splicing BP. Subsequently, this protein acts as a "bridge" between BP and PPT and stabilizes the spliceosomal complex necessary for the first stage of the splicing reaction. In addition, our analysis of wild-type and mutated intron 4 predicted the loss of a significant number of binding motifs for hnRNP proteins from mutated intron 4 compared with wild type. However, mutated intron 4 maintained ability to recruit hnRNP, a protein which most likely contributes to the exclusion of exon 4 through its ability to dimerise with other molecules of hnRNP A located within and on adjacent introns (E). (F) Splicing of aberrant *HAS1* Vb transcripts in transfected HeLa cells. The diagram shows the expression cassettes for *HAS1* minigene constructs. *HAS1* sequences were flanked by a mammalian CMV promoter at the 5' end of *HAS1* gene and the bovine growth hormone polyadenylation signal, poly A, at the 3' end. mRNA splicing was analyzed by transfecting HeLa cells with *HAS1* minigene cassettes. RT-PCR was performed 24 hours after transfection, using specific primers for *HAS1* full-length (FL), *HAS1*Vb or β<sub>2</sub>m (β-2 microglobulin). On the gel, Ø indicates the result obtained from the cells transfected with cassette without *HAS1* gene; FL, the result obtained from the cells transfected with pcDNA3-HAS1-FL cDNA construct, which is already spliced; Lanes 1 to 4 represent HeLa cells transfected with pcDNA3-HAS1-g3-4-5 construct. We tested 4 subclones of the *HAS1* minigene cassette; transfection of all 4 subclones gave identical results. Product identity was confirmed by sequencing. For this experiment, Ø and FL were used as controls to verify specificity of the in vitro splicing assay.



thereby leaving a mutational “trace” in nonmalignant HPCs and T cells as well as in malignant B cells and PCs, with the largest number of GV mutations occurring in malignant MM and WM cells. In patients with MM and WM, we identified 3 categories of genetic change: inherited germline origin, acquired hematopoietic origin, and acquired tumor-specific GV mutations. All types included recurrent *HAS1* GV mutations, defined by their detection in 2 or more patients with MM or patients with WM. The majority of germline GV mutations and all recurrent acquired *HAS1* GV mutations were absent from the 23 control subjects.

Of the 197 novel GV mutations reported here, 50 were recurrent and 147 were unique. We anticipate that when larger cohorts are analyzed, some of the GV mutations currently classified as unique will prove to be recurrent. Recurrent somatic GV mutations are restricted to MM, restricted to WM, or shared by both MM and WM; none are detected in the 23 control subjects. The majority of recurrent GV mutations (both inherited and acquired), including 3 recurrent tumor-specific GV mutations, are shared between MM and WM. Although global gene expression profiling suggests that WM has more in common with B-CLL than with MM,<sup>46</sup> genomic analysis of *HAS1* indicates that MM and WM, but not B-CLL, share a very close genetic relationship. The acquisition of recurrent somatic changes in the *HAS1* gene, particularly in the noncoding intron 4, suggests that the *HAS1* gene undergoes hypermutation and that strong selective pressures enrich these GV mutations in MM and WM.

Somatic mutations with the potential to alter splicing are frequent in some cancers.<sup>28,36,44,47,48</sup> In patients with MM and WM we detected 87 somatic GV mutations, including 61 tumor-specific and 26 of hematopoietic-origin on *HAS1* exons and introns (Table 3). MM and WM are B-lineage cancers. In malignant B cells, aberrant somatic hypermutation affects genes outside of the immunoglobulin variable region,<sup>49-54</sup> which may occur before neoplastic transformation.<sup>51</sup> The frequency of hypermutated genes such as *BCL-6* and *PAX5* ranges from approximately 0.2 to 0.6/100 bp,<sup>49-54</sup> consistent with the degree of hypermutation detected within the *HAS1* gene in MM and WM (~0.1-0.5/100 bp).

Somatic GV mutations were found in all subsets of differentiated hematopoietic cells (PCs, PB B and T cells) and in purified CD34<sup>+</sup> HPCs. Somatic GV mutations were found in G-CSF–mobilized blood autografts or bone marrow from all 8 patients from whom HPCs were available. This implies that somatic *HAS1* GV mutations may be acquired at the earliest stages of hematopoietic development. HPCs harboring somatic *HAS1* GV mutations have normal generative capabilities and are clearly nonmalignant, because their nonmalignant T-cell progeny carry the same somatic GV mutations. Our previous work shows that *HAS1Vb* transcripts are found in MM and WM cells but are undetectable in nonmalignant MM HPCs or MM T cells and normal B cells.<sup>10,12</sup> Because at birth HPCs must, by definition, have the same genotype as BECs, our work suggests that in persons who are destined for MM and WM, an undefined mechanism may enrich those HPCs that have acquired somatic *HAS1* GV mutations.

The pattern of germline GV mutations suggests that MM and WM, but not B-CLL, inherit recurrent germline GV mutations that are necessary but not sufficient for progression to malignancy. Acquisition of recurrent, somatic *HAS1* GV mutations in otherwise healthy HPCs from patients with MM and WM appears to further increase the risk of MM or WM. This idea is supported by our demonstration that transfection of a *HAS1*-splicing construct from a patient with WM directs the aberrant splicing of *HAS1Vb* (in vitro splicing assay). The B-cell stage, at which acquisition of critical

tumor-specific GV mutations occurs, may determine whether a person develops MM or WM. Our work suggests that, similar to leukemias, genetic changes leading to myelomagenesis may first accumulate in HPCs during the nonmalignant or premalignant stages of hematopoietic differentiation.<sup>55-57</sup> The presence of tumor-specific recurrent GV mutations restricted to MM B cells or PCs, coupled with expression of clinically predictive aberrant *HAS1Vb* transcripts by B cells,<sup>10</sup> supports the concept that transforming events may occur at the B-cell stage,<sup>44,58</sup> and that malignant B cells transfer mutated *HAS1* alleles to their MM PC progeny.

Provocatively, clusters of recurrent GV mutations are localized at sites of the *HAS1* gene that control pre-mRNA splicing, particularly in intron 4, as shown in Figures 2B and 3. NCBI *HAS1* SNPs appear to be significant predisposing elements in oncogenesis, as evidenced by their presence in combination with the common motif detected on the *HAS1* gene. In silico analysis predicted that this common motif contributes to aberrant *HAS1* splicing. To support the idea that *HAS1* GV mutations play a role in *HAS1* aberrant splicing, we conducted an in vitro splicing assay using a *HAS1* splicing cassette genetically engineered from gDNA of a patient with WM. The successful in vitro splicing of *HAS1Vb* verified bioinformatic predictions that the GV mutations (particularly aberrations in the common motif region of first and second T and TTTA stretches of the *HAS1* cassette) would direct splicing of *HAS1Vb* after transfection with the WM *HAS1* cassette of host cells that do not otherwise express *HAS1* or *HAS1Vb* transcripts.

The *HAS1* GV mutations described here and the aberrant splicing reported previously<sup>10</sup> are probably important in malignancy. The aberrant *HAS1* splice variants synthesize HA in ex vivo MM cells<sup>10</sup> and in transfectants (A.G., H.K., and L.M.P., manuscript submitted). In ex vivo MM cells from patients, *HAS1Va* correlates with synthesis of extracellular HA and *HAS1Vb* is associated with synthesis of intracellular HA,<sup>10</sup> suggesting a contribution to, respectively, malignant spread<sup>59</sup> and altered mitosis.<sup>60</sup> In *HAS1* transfectants, normally spliced *HAS1* (*HAS1-FL*) has a short half-life and localizes to the plasma membrane, whereas the *HAS1* splice variants have a prolonged half-life and localize to the cytoplasm (A.G., H.K., and L.M.P., manuscript submitted). The aberrant splice variants form hetero-multimers with *HAS1-FL* and each other, thereby prolonging the half-life of *HAS1-FL* and providing a potential mechanism for promoting cancer (A.G., H.K., and L.M.P., manuscript submitted). Finally, as a single agent of an intronic splice variant, *HAS1Vc* is aggressively transforming in vitro and forms tumors in vivo (A.G., H.K., and L.M.P., manuscript submitted). It seems likely that *HAS1* family members will act synergistically among themselves and with other molecules, for example RHAMM,<sup>60-63</sup> to confer malignant characteristics. Work is in progress to evaluate this.

If verified in large-scale studies, the recurrent *HAS1* GV mutations identified here may have the potential to identify persons at risk of MM or WM. Persons with germline *HAS1* GV mutations are predicted to have some degree of risk of developing MM or WM. Persons who, in addition to inheriting *HAS1* germ line GV mutations have acquired *HAS1* GV mutations, may have a greatly increased risk of developing MM (or WM), perhaps requiring closer monitoring. The possibility exists that early detection of acquired *HAS1* mutations may identify cryptic early stages of MM or WM. Overall, this work shows that inherited and acquired *HAS1* GV mutations may contribute to the development of overt disease or disease progression in MM and WM by directing the aberrant intronic splicing of *HAS1*.

## Acknowledgments

We thank Carolyn McQuarrie, Erin Strachan, Juanita Wizniak, and Sarah Motz for skilled technical assistance, and Daniel Santos for his help in obtaining WM samples.

This work was supported by grants from the Canadian Institutes of Health Research, the Alberta Cancer Research Institute, the International Waldenstrom Macroglobulinemia Foundation, and the Alberta Cancer Board Research Initiatives Program. S.A. was supported by an AHFMR Studentship. T.R. is an AHFMR Clinical Investigator. L.M.P. is the Canada Research Chair in Biomedical Nanotechnology and this work was supported in part by the Chairs Program.

## References

- Buratti E, Baralle M, Baralle FE. Defective splicing, disease and therapy: searching for master checkpoints in exon definition. *Nucleic Acids Res*. 2006;34:3494-3510.
- Kalnina Z, Zayakin P, Silina K, Line A. Alterations of pre-mRNA splicing in cancer. *Genes Chromosomes Cancer*. 2005;42:342-357.
- Venables JP. Aberrant and alternative splicing in cancer. *Cancer Res*. 2004;64:7647-7654.
- Knudsen KE, Diehl JA, Haiman CA, Knudsen ES. Cyclin D1: polymorphism, aberrant splicing and cancer risk. *Oncogene*. 2006;25:1620-1628.
- Lamolle G, Marin M, Alvarez-Valin F. Silent mutations in the gene encoding the p53 protein are preferentially located in conserved amino acid positions and splicing enhancers. *Mutat Res*. 2006;600:102-112.
- Staalesen V, Falck J, Geisler S, et al. Alternative splicing and mutation status of CHEK2 in stage III breast cancer. *Oncogene*. 2004;23:8535-8544.
- Moon SD, Park JH, Kim EM, et al. A Novel IVS2-1G>A mutation causes aberrant splicing of the HRPT2 gene in a family with hyperparathyroidism-jaw tumor syndrome. *J Clin Endocrinol Metab*. 2005;90:878-883.
- Pagenstecher C, Wehner M, Friedl W, et al. Aberrant splicing in MLH1 and MSH2 due to exonic and intronic variants. *Hum Genet*. 2006;119:9-22.
- Lu F, Gladden AB, Diehl JA. An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene. *Cancer Res*. 2003;63:7056-7061.
- Adamia S, Reiman T, Crainie M, et al. Intronic splicing of hyaluronan synthase 1 (HAS1): a biologically relevant indicator of poor outcome in multiple myeloma. *Blood*. 2005;105:4836-4844.
- Adamia S, Crainie M, Kriangkum J, et al. Abnormal expression of hyaluronan synthases in patients with Waldenstrom's macroglobulinemia. *Semin Oncol*. 2003;30:165-168.
- Adamia S, Treon SP, Reiman T, et al. Single nucleotide polymorphism of hyaluronan synthase 1 gene and aberrant splicing in Waldenstrom's macroglobulinemia. *Clinical Lymphoma*. 2005;5:253-256.
- Simpson MA, Reiland J, Burger SR, et al. Hyaluronan synthase elevation in metastatic prostate carcinoma cells correlates with hyaluronan surface retention, a prerequisite for rapid adhesion to bone marrow endothelial cells. *J Biol Chem*. 2001;276:17949-17957.
- Liu N, Gao F, Han Z, et al. Hyaluronan synthase 3 overexpression promotes the growth of TSU prostate cancer cells. *Cancer Res*. 2001;61:5207-5214.
- Itano N, Sawai T, Atsumi F, et al. Selective expression and functional characteristics of three mammalian hyaluronan synthases in oncogenic malignant transformation. *J Biol Chem*. 2004;279:18679-18687.
- Itano N, Kimata K. Altered hyaluronan biosynthesis in cancer progression. *Semin Cancer Biol*. 2008;18:268-274.
- Yamada Y, Itano N, Narimatsu H, et al. Elevated transcript level of hyaluronan synthase 1 gene correlates with poor prognosis of human colon cancer. *Clin Exp Metastasis*. 2004;21:57-63.
- Yabushita H, Noguchi M, Kishida T, et al. Hyaluronan synthase expression in ovarian cancer. *Oncol Rep*. 2004;12:739-743.
- Bourguignon LY, Gilad E, Peyrollier K. Heregulin-mediated ErbB2-ERK signaling activates hyaluronan synthases leading to CD44-dependent ovarian tumor cell growth and migration. *J Biol Chem*. 2007;282:19426-19441.
- Golshani R, Hautmann SH, Estrella V, et al. HAS1 expression in bladder cancer and its relation to urinary HA test. *Int J Cancer*. 2007;120:1712-1720.
- Golshani R, Lopez L, Estrella V, et al. Hyaluronic acid synthase-1 expression regulates bladder cancer growth, invasion, and angiogenesis through CD44. *Cancer Res*. 2008;68:483-491.
- Yabushita H, Kishida T, Fusano K, et al. Role of hyaluronan and hyaluronan synthase in endometrial cancer. *Oncol Rep*. 2005;13:1101-1105.
- Carbone MA, Applegarth DA, Robinson BH. Intron retention and frameshift mutations result in severe pyruvate carboxylase deficiency in two male siblings. *Hum Mutat*. 2002;20:48-56.
- Chen LL, Sabripour M, Wu EF, et al. A mutation-created novel intra-exonic pre-mRNA splice site causes constitutive activation of KIT in human gastrointestinal stromal tumors. *Oncogene*. 2005;24:4271-4280.
- Eng L, Coutinho G, Nahas S, et al. Nonclassical splicing mutations in the coding and noncoding regions of the ATM Gene: maximum entropy estimates of splice junction strengths. *Hum Mutat*. 2004;23:67-76.
- Lazzereschi D, Nardi F, Turco A, et al. A complex pattern of mutations and abnormal splicing of Smad4 is present in thyroid tumours. *Oncogene*. 2005;24:5344-5354.
- Liu HX, Cartegni L, Zhang MQ, Krainer AR. A mechanism for exon skipping caused by nonsense or missense mutations in BRCA1 and other genes. *Nat Genet*. 2001;27:55-58.
- Serra E, Ars E, Ravella A, et al. Somatic NF1 mutation spectrum in benign neurofibromas: mRNA splice defects are common among point mutations. *Hum Genet*. 2001;108:416-429.
- Rutter JL, Goldstein AM, Davila MR, Tucker MA, Struewing JP. CDKN2A point mutations D153sp(c. 457G>T) and IVS2+1G>T result in aberrant splice products affecting both p16INK4a and p14ARF. *Oncogene*. 2003;22:4444-4448.
- Cartegni L, Chew SL, Krainer AR. Listening to silence and understanding nonsense: exonic mutations that affect splicing. *Nat Rev Genet*. 2002;3:285-298.
- Maquat LE. Defects in RNA splicing and the consequence of shortened translational reading frames. *Am J Hum Genet*. 1996;59:279-286.
- Hentze MW, Kulozik AE. A perfect message: RNA surveillance and nonsense-mediated decay. *Cell*. 1999;96:307-310.
- Valentine CR. The association of nonsense codons with exon skipping. *Mutat Res*. 1998;411:87-117.
- Bromidge T, Lowe C, Prentice A, Johnson S. p53 intronic point mutation, aberrant splicing and telomeric associations in a case of B-chronic lymphocytic leukaemia. *Br J Haematol*. 2000;111:223-229.
- Coutinho G, Xie J, Du L, et al. Functional significance of a deep intronic mutation in the ATM gene and evidence for an alternative exon 28a. *Hum Mutat*. 2005;25:118-124.
- Nichols KE, Houseknecht MD, Godmilow L, et al. Sensitive multistep clinical molecular screening of 180 unrelated individuals with retinoblastoma detects 36 novel mutations in the RB1 gene. *Hum Mutat*. 2005;25:566-574.
- Gamez-Pozo A, Palacios I, Kontic M, et al. Pathogenic validation of unique germline intronic variants of RB1 in retinoblastoma patients using minigenes. *Hum Mutat*. 2007;28:1245.
- Sharp A, Pichert G, Lucassen A, Eccles D. RNA analysis reveals splicing mutations and loss of expression defects in MLH1 and BRCA1. *Hum Mutat*. 2004;24:272.
- Hansen TV, Bisgaard ML, Jonson L, et al. Novel de novo BRCA2 mutation in a patient with a family history of breast cancer. *BMC Med Genet*. 2008;9:58.
- Agrawal S, Pilarski R, Eng C. Different splicing defects lead to differential effects downstream of the lipid and protein phosphatase activities of PTEN. *Hum Mol Genet*. 2005;14:2459-2468.
- Hull J, Shackleton S, Harris A. Abnormal mRNA splicing resulting from three different mutations in the CFTR gene. *Hum Mol Genet*. 1993;2:689-692.
- Durie BG, Kyle RA, Belch A, et al. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. *Hematol J*. 2003;4:379-398.
- Kyle RA, Treon SP, Alexanian R, et al. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International

- Workshop on Waldenstrom's Macroglobulinemia. *Semin Oncol.* 2003 Apr;30:116-120.
44. Szczepek AJ, Seeberger K, Wizniak J, et al. A high frequency of circulating B cells share clonotypic IgH VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single cell and in situ RT-PCR. *Blood.* 1998;92:2844-2855.
  45. National Center for Biotechnology Information. Human Genome Resources. [www.ncbi.nlm.nih.gov/projects/genome/guide/human/](http://www.ncbi.nlm.nih.gov/projects/genome/guide/human/). Accessed July 14, 2008.
  46. Chng WJ, Schop RF, Price-Troska T, et al. Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. *Blood.* 2006;108:2755-2763.
  47. Pros E, Larriba S, Lopez E, et al. NF1 mutation rather than individual genetic variability is the main determinant of the NF1-transcriptional profile of mutations affecting splicing. *Hum Mutat.* 2006;27:1104-1114.
  48. Schaffner C, Stilgenbauer S, Rappold GA, Dohner H, Lichter P. Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia. *Blood.* 1999;94:748-753.
  49. Pasqualucci L, Neri A, Baldini L, Dalla-Favera R, Migliazza A. BCL-6 mutations are associated with immunoglobulin variable heavy chain mutations in B-cell chronic lymphocytic leukemia. *Cancer Res.* 2000;60:5644-5648.
  50. Deutsch AJ, Aigelsreiter A, Staber PB, et al. MALT lymphoma and extranodal diffuse large B-cell lymphoma are targeted by aberrant somatic hypermutation. *Blood.* 2007;109:3500-3504.
  51. Malpeli G, Barbi S, Moore PS, et al. Primary mediastinal B-cell lymphoma: hypermutation of the BCL6 gene targets motifs different from those in diffuse large B-cell and follicular lymphomas. *Haematologica.* 2004;89:1091-1099.
  52. Gaidano G, Capello D, Cilia AM, et al. Genetic characterization of HHV-8/KSHV-positive primary effusion lymphoma reveals frequent mutations of BCL6: implications for disease pathogenesis and histogenesis. *Genes Chromosomes Cancer.* 1999;24:16-23.
  53. Pasqualucci L, Neumeister P, Goossens T, et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. *Nature.* 2001;412:341-346.
  54. Montesinos-Rongen M, Van RD, Schaller C, Wiestler OD, Deckert M. Primary diffuse large B-cell lymphomas of the central nervous system are targeted by aberrant somatic hypermutation. *Blood.* 2004;103:1869-1875.
  55. George AA, Franklin J, Kerkof K, et al. Detection of leukemic cells in the CD34(+)CD38(-) bone marrow progenitor population in children with acute lymphoblastic leukemia. *Blood.* 2001;97:3925-3930.
  56. Mauro MJ, Druker BJ. Chronic myelogenous leukemia. *Curr Opin Oncol.* 2001;13:3-7.
  57. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. *Nat Med.* 1997;3:730-737.
  58. Pilarski LM, Baigori E, Mant MJ, et al. Multiple myeloma includes CD20+ B and plasma cells that persist in patients treated with rituximab. *Clin Med Oncol.* 2008;2:275-285.
  59. Masellis-Smith A, Belch AR, Mant MJ, Turley EA, Pilarski LM. Hyaluronan-dependent motility of B cells and leukemic plasma cells in blood, but not of bone marrow plasma cells, in multiple myeloma: alternate use of receptor for hyaluronan-mediated motility (RHAMM) and CD44. *Blood.* 1996;87:1891-1899.
  60. Pilarski LM, Adamia S, Maxwell CA, et al. Hyaluronan synthases and RHAMM as synergistic mediators of malignancy in B lineage cancers. In: Balazs EA, Hascall VC, eds. *Hyaluronan Structure, Metabolism, Biological Activities, Therapeutic Applications.* Edgewater, NJ: Matrix Biology Institute; 2005:329-338.
  61. Maxwell CA, Keats JJ, Crainie M, et al. RHAMM is a centrosomal protein that interacts with dynein and maintains spindle pole stability. *Mol Biol Cell.* 2003;14:2262-2276.
  62. Maxwell CA, Rasmussen E, Zhan F, et al. RHAMM expression and isoform balance predicts aggressive disease and poor survival in multiple myeloma. *Blood.* 2004;104:1151-1158.
  63. Maxwell CA, Reiman T, Ye M, Belch AR, Pilarski LM. RHAMM overexpression: a potential mechanism to generate extensive centrosomal abnormalities in multiple myeloma [abstract]. *Blood.* 2003;102:35a.